

WHO Emergency Use Assessment Coronavirus disease (COVID-19) IVDs PUBLIC REPORT

Product: GLINE-2019-nCoV Ag (Self-Test)
Manufacturer: SHENZHEN YHLO BIOTECH CO., LTD.
EUL Number: EUL 0699-224-00
Outcome: Accepted

The EUL process is intended to expedite the availability of in vitro diagnostics needed in public health emergency situations and to assist interested UN procurement agencies and Member States in determining the acceptability of using specific products in the context of a Public Health Emergency of International Concern (PHEIC), based on an essential set of available quality, safety and performance data. The EUL procedure includes the following:

- Quality Management Systems Review and Plan for Post-Market Surveillance: desk-top review of the manufacturer's Quality Management System documentation and specific manufacturing documents;
- Product Dossier Review: assessment of the documentary evidence of safety and performance.

GLINE-2019-nCoV Ag (Self-Test), product codes G86256, G86257, G86278, G86279, G86280, and G86273, CE-mark regulatory version, manufactured by SHENZHEN YHLO BIOTECH CO., LTD, Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, China was listed on 11 July 2023.

Intended use:

According to the claim of intended use from SHENZHEN YHLO BIOTECH CO., LTD, "*GLINE-2019-nCoV Ag Test is a colloidal gold immunoassay (CGIA) for qualitative detection of SARS-CoV-2 nucleocapsid antigens in direct nasal swab from individuals who are suspected of SARS-CoV-2 within the first seven days of the onset of symptoms.*

Positive results indicate that viral antigens are present in the sample. Positive results do not exclude the possibility of bacterial infection or co-infection with other viruses.

Negative results do not exclude SARS-CoV-2 infection. SARS-CoV-2 infection or not should at least take into account your disease history, clinical signs, and symptoms consistent with COVID-19.

The GLINE-2019-nCoV Ag is intended for self-testing. Teenagers and children under 18 years old should follow the guidance from their guardians to perform a self-test. Elders above 80 should seek for assistance to perform a self-test."

Validated specimen type: Nasal swab specimens.

Test kit contents:

Component	1 test/kit (T/k) (G86256)	5T/kit (G86257)	7 T/kit (G86278)	10 T/kit (G86279)	15 T/kit (G86280)	20 T/kit (G86273)
Test Cassette (pcs)	1	5	7	10	15	20
Extraction Buffer, 400 µL/tube (pcs)	1	5	7	10	15	20
Sterile Swabs (pcs)	1	5	7	10	15	20
Biohazard Sample Bags (pcs)	1	5	7	10	15	20
Instruction For Use (pcs)	1	1	1	1	1	1

Materials required but not provided:

Timer

Storage

2-30°C.

Shelf-life upon manufacture:

18 months (real-time stability studies are ongoing).

Warnings/limitations:

Refer to the instructions for use (IFU).

Product dossier assessment

SHENZHEN YHLO BIOTECH CO., LTD submitted a product dossier for the GLINE-2019-nCoV Ag for detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen as per the “*Instructions for Submission Requirements: In vitro diagnostics (IVDs) Detecting SARS-CoV-2 Nucleic Acid and rapid diagnostics tests detecting SARS-CoV-2 antigens (PQDx_0347)*”. The information (data and documentation) submitted in the product dossier was reviewed by WHO staff and external technical experts (assessors) appointed by WHO.

Post listing Commitments for EUL:

As commitments to listing, SHENZHEN YHLO BIOTECH CO., LTD committed to:

1. Submit evidence of estimation of the product's Limit of Detection (LoD) with the WHO International Standard for SARS-CoV-2 antigen (NIBSC code: 21/368).

2. Submit simulated transport and ruggedness of packaging studies by July 2024.

The risk-benefit assessment is acceptable.

Quality Management Systems Review

To establish eligibility for WHO procurement, SHENZHEN YHLO BIOTECH CO., LTD was asked to provide up-to-date information about the status of their quality management system.

Based on the review of the submitted quality management system documentation by WHO staff, it was established that sufficient information was provided by SHENZHEN YHLO BIOTECH CO., LTD to fulfil the requirements described in the *“Instructions for Submission Requirements: In vitro diagnostics (IVDs) Detecting SARS-CoV-2 Nucleic Acid and rapid diagnostics tests detecting SARS-CoV-2 antigens (PQDx_347)”*.

The quality management documentation assessment is acceptable.

Plan for Post-Market Surveillance

Post-market surveillance, including monitoring all customer feedback, detecting and acting on adverse events, product problems, non-conforming goods and processes is a critical component of minimizing potential harm of an IVD listed for emergency use.

The following post-EUL activities are required to maintain the EUL listing status:

1. Notification to WHO of any planned changes to a EUL product, in accordance with *“WHO procedure for changes to a WHO prequalified in vitro diagnostic”* (document number PQDx_121); and
2. Post-market surveillance activities, in accordance with *“Guidance for post-market surveillance and market surveillance of medical devices, including in vitro diagnostics”* (ISBN 978-92-4-001531-9).

SHENZHEN YHLO BIOTECH CO., LTD is also required to report all categories of complaints in a summarized form. There are certain categories of complaints and changes to the product that must be notified immediately to WHO, as per the above-mentioned documents.

The manufacturer has committed to ensuring that post-emergency use listing safety, quality, and performance monitoring activities are in place, per WHO guidance *“Guidance for post-market surveillance and market surveillance of medical devices, including in vitro diagnostics”* (ISBN 978-92-4-001531-9).¹

¹ Available on the web page

<https://www.who.int/publications/i/item/guidance-for-post-market-surveillance-and-market-surveillance-of-medical-devices-including-in-vitro-diagnostics>

Scope and duration of procurement eligibility

GLINE-2019-nCoV Ag (Self-Test), product codes G86256, G86257, G86278, G86279, G86280, and G86273, manufactured by SHENZHEN YHLO BIOTECH CO., LTD, is considered to be eligible for WHO procurement for 12 months from the day of listing. The assay may be used for the detection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen. This listing does not infer that the product meets WHO prequalification requirements and does not mean that the product is listed as WHO-prequalified.

As part of the ongoing requirements for listing as eligible for WHO procurement, SHENZHEN YHLO BIOTECH CO., LTD must engage in post-market surveillance activities to ensure that the product continues to meet safety, quality and performance requirements. SHENZHEN YHLO BIOTECH CO., LTD is required to notify WHO of any complaints, including adverse events related to the use of the product, within 7 days and any changes to the product.

WHO reserves the right to rescind eligibility for WHO procurement if additional information on the safety, quality, and performance during post-market surveillance activities and if new data becomes available to WHO that changes the risk-benefit balance.

Labelling

1.0 Labels

2.0 Instructions for Use (IFU)

1.0 Product labels

1.1 Outer box artwork and labels

YHLO



1 TEST

COVID-19 Test:
A colloidal gold immunoassay (CGIA) for qualitative
detection of SARS-CoV-2 nucleocapsid antigens in
direct nasal swab.

FOR SELF-TESTING

GLINE-2019-nCoV Ag




REF G86256

LOT



Workflow of GLINE-2019-nCoV Ag



GLINE-2019-nCoV Ag
contains:

- 1 Test Cassette
- 1 Extraction Buffer
- 1 Biohazard Sample Bag
- 1 Sterile Swab
- 1 Instruction for Use




SHENZHEN YHLO BIOTECH CO., LTD.
Building 1, YHLO Biopark, Baoqing 2nd Road,
Shibei Shizhen, PEOPLE'S REPUBLIC OF CHINA.


CE mark
Loush N.E.V.
The Hoque, Kerpentien,
Koningin Astridkopen 10, 1640, 2595AA,
E-mail: info@yhlolab.com



YHLO | SHENZHEN YHLO BIOTECH CO., LTD.

Label for the box






Label for the extraction buffer



Label for the sterile swabs



Label for Test cassette foil pouch

YHLO



7 TESTS


COVID-19 Test:
A colloidal gold immunosorbent assay (CGIA) for qualitative
detection of SARS-CoV-2 nucleocapsid antigens in
direct nasal swab.



GLINE-2019-nCoV Ag

FOR SELF-TESTING

Workflow of GLINE-2019-nCoV Ag



YHLO | SHENZHEN YHLO BIOTECH CO., LTD.

REF G86278

LOT



GLINE-2019-nCoV Ag contains:

For self-testing:

- 7 Test Cassettes
- 7 Extraction Buffer
- 7 Biohazard Sample Bags
- 7 Sterile Swabs
- 1 Instruction for Use



COVID-19




Operation Video

YHLO | SHENZHEN YHLO BIOTECH CO., LTD.

SHENZHEN YHLO BIOTECH CO., LTD.
Building 1, YHLO Biopark, Baolong 2nd Road,
Baolong Subdistrict, Longgang District,
518116 Shenzhen, PEOPLE'S REPUBLIC OF CHINA

EC REP Lotus NL B.V.
Koningin Julianaplein 10, 1e Verd, 2595AA,
The Hague, Netherlands.
E-mail: peter@lotusnl.com







Label for the extraction buffer



Label for the sterile swabs




Label for Test cassette foil pouch



Label for the extraction buffer



Label for the sterile swabs




Label for Test cassette foil pouch

YHLO



15 TESTS


COVID-19 Test:
A colloidal gold immunoassay (CGIA) for qualitative detection of SARS-CoV-2 nucleocapsid antigens in direct nasal swab.



FOR SELF-TESTING

GLINE-2019-nCoV Ag

Workflow of GLINE-2019-nCoV Ag



YHLO | SHENZHEN YHLO BIOTECH CO., LTD.

REF G86280

LOT



GLINE-2019-nCoV Ag contains:



For self-testing:

- 15 Test Cassettes
- 15 Extraction Buffer
- 15 Biohazard Sample Bags
- 15 Sample Bags
- 1 Instruction for Use




Operation Video

YHLO | SHENZHEN YHLO BIOTECH CO., LTD.

SHENZHEN YHLO BIOTECH CO., LTD.
 Building 1, YHLO Biopark, Baolong 2nd Road,
 Baolong Subdistrict, Longgang District,
 518116 Shenzhen, PEOPLE'S REPUBLIC OF CHINA

EC REP Lotus NL B.V.
 Koningin Julianaplein 10, 1e Verd, 2595AA,
 The Hague, Netherlands.
 E-mail: peter@lotusnl.com






Label for the extraction buffer




Label for the sterile swabs



Label for Test cassette foil pouch



YHLO



Rapid Test

20 TESTS


COVID-19 Test:
A colloidal gold immunoassay (CGIA) for qualitative detection of SARS-COV-2 nucleocapsid antigens in direct nasal swab.

FOR SELF-TESTING

GLINE-2019-nCoV Ag



Workflow of GLINE-2019-nCoV Ag



SHENZHEN YHLO BIOTECH CO., LTD.
Building 1, YHLO Biopark, Baoqiang 2nd Road,
Baoqiang Subdistrict, Longgang District,
518116 Shenzhen, PEOPLE'S REPUBLIC OF CHINA

Lotus NL B.V.
Koningin Julianaplein 10, 1e Verd, 2595AA,
The Hague, Netherlands.
E-mail: peter@lotusnl.com

GLINE-2019-nCoV Ag
contains:

EN For Self-testing

- 20 Test Cassettes
- 20 Extraction Buffer
- 20 Biohazard Sample Bags
- 20 Sterile Swabs
- 1 Instruction for Use



Operation Video

YHLO

GLINE-2019-nCoV Ag

FOR SELF-TESTING

COVID-19 Test:
A colloidal gold immunoassay (CGIA) for qualitative detection of SARS-COV-2 nucleocapsid antigens in direct nasal swab.

20 TESTS



Rapid Test




YHLO | SHENZHEN YHLO BIOTECH CO., LTD.

REF G86273

LOT




6 925912 713318



Label for the extraction buffer



Label for the sterile swabs



Label for Test cassette foil pouch

2.0 Instructions for use²

² English version of the IFU was assessed by WHO. It is the responsibility of the manufacturer to ensure correct translation into other languages.

ENGLISH

CE 1434 For self-testing

IVD *In vitro* diagnostic medical device**INTENDED USE**

The GLINE-2019-nCoV Ag Test is a colloidal gold immunoassay (CGIA) for qualitative detection of SARS-CoV-2 nucleocapsid antigens in direct nasal swab from individuals who are suspected of SARS-CoV-2 within the first seven days of the onset of symptoms. Positive results indicate that viral antigens are present in the sample. Positive results do not exclude the possibility of bacterial infection or co-infection with other viruses.

Negative results do not exclude SARS-CoV-2 infection. SARS-CoV-2 infection or not should at least take into account your disease history clinical signs and symptoms consistent with COVID-19.

The GLINE-2019-nCoV Ag is intended for self-testing. Teenagers and children under 18 years old should follow the guidance from their guardians to perform a self-test. Elders above 80 should seek for assistance to perform a self-test.

SUMMARY AND EXPLANATION

The novel coronaviruses belong to the β genus. COVID-19 is an acute respiratory infectious disease.

People are generally susceptible. Currently, the patients infected by the novel coronavirus are the main source of infection; asymptomatic infected people can also be an infectious source. Based on the current epidemiological investigation, the incubation period is 1 to 14 days, mostly 3 to 7 days but still remains infectious during this period. The main manifestations include fever, fatigue and dry cough. Nasal congestion, runny nose, sore throat, myalgia and diarrhea are found in a few cases.

PRINCIPLE OF THE TEST

The GLINE-2019-nCoV Ag Test employs colloidal gold immunoassay technology in a sandwich design to detect the SARS-CoV-2 nucleocapsid protein.

- When specimens are processed and added into sample well, the specimen will flow along the test strip by capillary action. If the SARS-CoV-2 nucleocapsid protein exists in the specimen, the protein will combine with colloidal gold labeled SARS-CoV-2 antibodies. This immune complex will be captured by immobilized anti-SARS-CoV-2 antibodies in the detection region (T) and form a coloured detection line, which means SARS-CoV-2 antigen positive.
- The detection cassette also includes a control region(C). Upon completion of a valid test, a coloured control line should appear regardless of whether the SARS-CoV-2 antigen is present in the sample. If the control line does not appear, the test result is invalid and the sample should be retested with another test cassette.

KIT COMPONENTS

GLINE-2019-nCoV Ag contains:

Components	REF	G86256	G86257	G86278	G86279	G86280	G86273
Test Cassette (pcs)		1	5	7	10	15	20
Extraction Buffer, 400 μ L/tube (pcs)		1	5	7	10	15	20
Sterile Swabs (pcs)		1	5	7	10	15	20
Biohazard Sample Bags (pcs)		1	5	7	10	15	20
Instruction For Use (pcs)		1	1	1	1	1	1

MATERIALS REQUIRED (BUT NOT PROVIDED)

- Timer.

WARNINGS AND PRECAUTIONS

IVD For *in vitro* diagnostic use only.

- Read instructions prior to performing the test. Follow all instructions to achieve accurate results.
- Use immediately after opening the pouch containing the test cassette.
- Avoid touching any bleeding areas of the nostril area during specimens collection, as excess blood or mucus on the swab may interfere with the test and yield a false result.
- Each single Test Cassette, Sterile Swab, Extraction Buffer and Biohazard Sample Bag are single use. Do not reuse individual components.
- Do not dip the Sterile Swab into buffer or other liquid before inserting the Swab into the nose.

- The provided Sterile Swab should be used only for nasal specimen collection.
- Do not use if the package of test device is damaged.
- Do not use if the package of sterile swabs is damaged.
- Do not use the kit contents beyond the expiration date.
- Do not eat, drink, or smoke in the area where the specimens and kit contents are handled.
- Do not interchange kit contents from different lots.
- Do not make any medical decision without first consulting your medical practitioner.
- Clean and disinfect all spills of specimens or buffer using appropriate disinfectant, eg. 75% alcohol.
- Please take the necessary safety measures (e.g. face mask, gloves) when testing for other people.
- If the extraction buffer makes contact with the skin or eye, wash/ flush with a large volume of water. If skin irritation, rash or other abnormal reaction occurs, please get medical advice/attention.
- Children and elders please use the test under the guardian assistance.
- Keep the test kit out of reach of children.
- Direct swab specimen should be tested immediately after collection.
- To prevent contamination, only touch the sides of the Test Device and ensure the Swab end only touches the nasal cavity and inside of Buffer Tube
- If the test has been stored in a refrigerator, allow the test to equilibrate to room temperature (20-30°C) for 30 minutes before use.
- If the test does not work or its performance changes, please repeat test procedure with a new test kit or contact manufacturer.

LIMITATIONS

- The accuracy of the test relies on the whole testing procedure being performed correctly. Failure to follow the instructions will adversely affect test accuracy. Retesting is recommended to confirm the results if the test results are inconsistent with clinical symptoms.
- This product is only used for qualitative detection of SARS-CoV-2 antigens in human nasal swab specimens and cannot quantitatively detect antigen concentration in samples.
- A confirmed diagnosis should only be made by a health care professional after all clinical and laboratory findings have been evaluated.
- Negative results in cases where COVID-19 disease is suspected should be reviewed by a confirmatory test if necessary.
- False negative results are more likely to occur if the test is not performed within the first 7 days of symptom onset.
- The tests are less reliable in the later phase of infection and in asymptomatic individuals.
- There is a higher chance of false-negative results with Ag RDT self-tests than with laboratory-based nucleic acid test.
- Repeat testing (e.g. 1-3 days) is recommended if there is an ongoing suspicion of infection, being in a high risk setting or where there is an occupational risk or other requirements.
- The negative results may not mean a person is not infectious and if symptoms continue, you are also advised to continue following local guidelines for self-isolation and consult your doctor.
- A negative result does not rule out infection with another respiratory pathogen.
- Improper collection, handling, transport of samples, or low virus in samples may also cause false negative results.
- Reading the test results earlier than 15 minutes or later than 20 minutes may give incorrect results.
- The results may be affected if the test is used in environments with humidity greater than 75%.

STORAGE AND STABILITY

- The product should be stored at 2-30°C, dry and out of light, its validity for 18 months.
- Each test cassette should be used immediately after opening the sealed foil pouch. The test should be used in a room temperature (20-30°C) environment.

FREQUENTLY ASKED QUESTIONS**What are the symptoms of COVID-19?**

The most common symptoms of COVID-19 are: fever, dry cough and fatigue. Other less common symptoms that may affect some patients include: loss of taste or smell, nasal congestion, conjunctivitis (also known as red eyes), sore throat, headache, muscle or joint pain, different types of skin rash, nausea or vomiting, diarrhea, chills or dizziness. People of all ages who experience fever and/or cough associated with difficulty breathing or shortness of breath, chest pain or pressure, or loss of speech or movement should seek medical care immediately. If possible, call your health care provider, hotline or health facility first, so you can be directed to the right clinic.

When should I get a test for COVID-19?

Anyone with symptoms should be tested, wherever possible. People who do not have symptoms but have had close contact with someone who is, or may be, infected may also consider testing - contact your local health guidelines and follow their guidance.

What should I do if I get a negative test result?

A negative test result means that proteins from the virus that causes COVID-19 was not detected. You might not have COVID-19. However, a negative result does not rule out the risk of COVID-19 infection. This means you possibly still have COVID-19 even though the test result is negative. If you continue to experience COVID-19 like symptoms such as headaches, migraines, fever, loss of smell or taste, contact your doctor or health department for advice on whether a PCR test is required. In addition, you can repeat the test with a new test kit. In case of suspicion, you could repeat the test after 1-2 days because can't be precisely detected in all phases of infection.

What should I do if I get a positive test result?

A positive test result means that proteins from the virus that causes COVID-19 was detected. It is likely that you will need to perform self-isolation at home to prevent the spread of COVID-19. A positive result does not rule out coinfection with other pathogens. Please follow local guidelines for self-isolation and immediately contact your doctor or local health department.

What should I do if I get an invalid test result?

You might not correctly perform the test. You should read the instructions again and repeat the procedure with a new test kit or contact manufacturer.

How accurate is the GLINE-2019-nCoV Ag?

The GLINE-2019-nCoV Ag test has been shown in a clinical study involving 653 direct nasal swabs, performed by 2 locations and tested immediately after collection, to correctly identify 99.30% (424 out of 427) of SARS-CoV-2 negative nasal samples (known as test specificity). The test correctly identified 90.27% (204 out of 226) SARS-CoV-2 positive nasal samples (known as test sensitivity). Results from the GLINE-2019-nCoV Ag test were compared with a reference RT-PCR assay.

REFERENCES

- Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature, 2020.
- Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding[J]. Lancet, 2020.

SHENZHEN YHLO BIOTECH CO., LTD.
Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, PEOPLE'S REPUBLIC OF CHINA
E-mail: info@szyhlo.com 24h Service Hotline: +86-400-166-0755



Lotus NL B.V.
Koningin Julianaplein 10, 1e Verd, 2595AA, The Hague, Netherlands.
E-mail: peter@lotusnl.com

ANNEX A: Explanation of abbreviation

Abbreviation	Explanation
	Catalogue number
	Contains sufficient for <n> tests
	Manufacturer
	Authorized representative in the European Community
	Caution
	Consult instructions for use
	In vitro diagnostic medical device
	Batch code
	Date of manufacture
	Use-by date
	Temperature limit (2-30 °C)
	This way up
	Do not re-use
	Do not use if package is damaged
	Keep dry
	Keep away from sunlight
	CE Conformity Marking

INSTRUCTIONS FOR USE

Please scan the QR code to watch the video of instructions before testing.



TEST PROCEDURE

Step 1:
Wash or disinfect your hands. Ensure they are dry before testing.

Step 7:
Insert the soft end of swab into the bottom of extraction buffer tube.

Step 2:
Ensure the completeness of components and check the expiration date on the box. Do not use if the component is damaged or if the kit is expired.

Step 8:
Squeeze the tube around the soft end of swab up and down in the fluid at least 15 seconds.

Step 3:
Take out the sterile swab from package. Do not touch the soft end of swab.

Step 9:
Remove the swab while squeezing the sides of the tube to release the liquid from the swab.

Step 4:
Carefully insert the soft end of swab into at about 1.5 cm of your nostril and gently rotate the swab at least 5 times.

x5 Times

Step 10:
Immediately place the processed swab in the biohazard sample bag to avoid virus spreading. The swab may contain infectious material and infecting other person.

Step 5:
Slowly remove the swab from your nostril. Using the same swab, repeat step 5 in your other nostril.

x5 Times

Step 11:
Press the included cap tightly onto the extraction buffer tube. Mix the fluid thoroughly by swirling or flicking the bottom of the tube.

Step 6:
Peel off the foil film of extraction buffer tube. Set the tube on the stand hole of the package box.

Step 12:
Place the test cassette on a well-lit, flat surface. Invert the extraction buffer tube and hold it vertically. Gently squeeze the body of tube, adding 3 drops of liquid into the sample well. DO NOT add more than 3 drops. Start the timer immediately after adding the extracted specimen to the specimen well of the test cassette.

x3 drops

Step 13:
Read the results 15-20 minutes after adding liquid to the sample well. Results read before 15 minutes or after 20 minutes may be invalid.

⚠ IMPORTANT: Do not move or lift the test cassette when reading the result.

Step 14:
After reading test result, place all components of the test device in the biohazard sample bag and dispose of it according to local regulation. Do not reuse any used components.

READ TEST RESULTS


Positive	Negative
Both Control (C) line and Test (T) line are present. Line intensities may vary from faint to strong intensity. A faint test line is also considered as a positive result.	The Control (C) line is present and no Test (T) line is present.



It's very likely you have COVID-19. You should follow local guidelines for self-isolation and immediately contact your doctor or local health department.

This indicates virus causing COVID-19 is not detected. You are unlikely to have COVID-19. If the viral load is too low (<2×10² TCID₅₀/mL) or too high (1.6×10⁵ TCID₅₀/mL), it will also lead to false-negative result. A negative result does not rule out the risk of COVID-19 infection. Please take personal protection following the local guideline and constantly monitor self healthy condition.

Invalid	DISPOSAL
No Control (C) line is present.	After reading test result, place all components of the test device in the biohazard sample bag and dispose of it according to local regulation. Do not reuse any used components.



The test does not work. You should read the instructions again and repeat the procedure with a new test kit or contact manufacturer.